☆ 4.6 Article

HS-10352 in hormone receptor-positive, HER2-negative advanced breast cancer: A phase 1 dose-escalation trial

CANCER MEDICINE (2023)

Related references

Note: Only part of the references are listed.

Review Oncology

Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy

Devesh Tewari et al.

Summary: This article emphasizes the role of the PI3K-Akt-mTOR signaling pathway in different cancer conditions and the importance of natural products as potential targets for cancer therapy. Additionally, it summarizes and analyzes various preclinical and clinical studies on bioactive compounds derived from natural products that target the PI3K-Akt-mTOR pathway.

SEMINARS IN CANCER BIOLOGY (2022)

Add to Collection

Article Oncology

Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant

Sara M. Tolaney et al.

Summary: This exploratory analysis assessed the efficacy of abemaciclib plus fulvestrant in patients with or without PIK3CA or ESR1 mutations in hormone receptor-positive, HER2-negative advanced breast cancer. The results showed that abemaciclib plus fulvestrant was effective regardless of PIK3CA or ESR1 mutation status, improving progression-free survival and overall survival. The improvement in median progression-free survival was more significant in the PIK3CA or ESR1 mutant tumor subgroups compared to the wild-type subgroups.

CLINICAL CANCER RESEARCH (2022)

Add to Collection

Article Oncology

Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer

Le Yu et al.

Summary: This article reviews the mechanisms leading to the hyperactivation of PI3K/Akt/mTOR signaling in cancer and summarizes the efforts in developing PI3K/Akt/mTOR inhibitors as monotherapy or combination therapy in different cancer settings. Targeting the PI3K/Akt/mTOR signaling pathway through the development of new agents, drug delivery systems, or combination regimens provides insights into possible future directions for targeted therapeutic regimen and effective patient stratification strategy to improve clinical outcomes for cancer patients with deregulated PI3K/Akt/mTOR signaling.

SEMINARS IN CANCER BIOLOGY (2022)

Add to Collection

Review Medicine, General & Internal

The Present and Future of Clinical Management in Metastatic Breast Cancer

Pauline H. Lin et al.

Summary: Breast cancer remains one of the common types of malignancy worldwide, despite the advances in early detection and treatment. Extensive research has led to a better understanding of its drivers and molecular characteristics, allowing for the classification into different subtypes. These subtypes have distinct treatment approaches based on immunohistological markers and transcriptomic signatures.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Review Biochemistry & Molecular Biology

PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects

Daniela Miricescu et al.

Summary: Breast cancer is a complex disease with various factors contributing to its pathogenesis. Current research is focused on the PI3K/AKT/mTOR signaling pathway and related cancer mutations. Clinical trials are also evaluating the efficacy of inhibitors targeting these signaling pathways in breast cancer treatment.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Oncology

PIK3CA somatic alterations in invasive breast cancers: different spectrum from Caucasians to Chinese detected by next generation sequencing

Minghan Jia et al.

Summary: PIK3CA alterations are prevalent in Chinese breast cancer patients with different molecular features compared to Caucasians. These findings provide valuable insights for the application of PIK3CA inhibitors in Chinese patients.

BREAST CANCER (2021)

Add to Collection

Article Oncology

Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial

S. Dent et al.

Summary: The SANDPIPER study demonstrated that Taselisib plus fulvestrant significantly improved progression-free survival in patients with PIK3CA-mutant breast cancer. However, due to safety concerns and modest clinical benefit, the combination therapy does not have clinical utility.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Oncology

Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update

Harold J. Burstein et al.

Summary: This study updated the treatment guidelines for hormone receptor (HR)-positive metastatic breast cancer, highlighting the importance of Alpelisib in combination with endocrine therapy, PIK3CA mutation testing, drug selection for BRCA1 or BRCA2 mutation carriers, and the use of CDK4/6 inhibitors in different patient populations.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Frequency and spectrum of PIK3CA somatic mutations in breast cancer

Olga Martinez-Saez et al.

BREAST CANCER RESEARCH (2020)

Add to Collection

Review Oncology

Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer

Pauline du Rusquec et al.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer

Fabrice Andre et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Review Oncology

Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review

Ricardo L. B. Costa et al.

BREAST CANCER RESEARCH AND TREATMENT (2018)

Add to Collection

Article Oncology

Phosphatidylinositol 3-Kinase -Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study

Dejan Juric et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Review Oncology

PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux

Jake S. O'Donnell et al.

SEMINARS IN CANCER BIOLOGY (2018)

Add to Collection

Article Oncology

A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers

Udai Banerji et al.

CLINICAL CANCER RESEARCH (2018)

Add to Collection

Article Oncology

Dual association of serum interleukin-10 levels with colorectal cancer

Shabnam Abtahi et al.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS (2017)

Add to Collection

Article Oncology

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Jose Baselga et al.

LANCET ONCOLOGY (2017)

Add to Collection

Article Oncology

Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors

Dejan Juric et al.

CANCER DISCOVERY (2017)

Add to Collection

Review Biochemistry & Molecular Biology

The PI3K Pathway in Human Disease

David A. Fruman et al.

CELL (2017)

Add to Collection

Article Multidisciplinary Sciences

The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes

Bernard Pereira et al.

NATURE COMMUNICATIONS (2016)

Add to Collection

Article Oncology

Benefit Mixed with Caution for Buparlisib

Cancer Discovery (2016)

Add to Collection

Article Oncology

First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014

Bristi Basu et al.

CLINICAL CANCER RESEARCH (2015)

Add to Collection

Article Cell Biology

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer

Ana Bosch et al.

SCIENCE TRANSLATIONAL MEDICINE (2015)

Add to Collection

Article Oncology

US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status

Nadia Howlader et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)

Add to Collection

Review Medicine, Research & Experimental

Mechanisms of Endocrine Resistance in Breast Cancer

C. Kent Osborne et al.

ANNUAL REVIEW OF MEDICINE, VOL 62, 2011 (2011)

Add to Collection

Article Medicine, Research & Experimental

A wide-spectrum paired comparison of the properties of the Rolling 6 and 3+3 Phase I study designs

Richard Sposto et al.

CONTEMPORARY CLINICAL TRIALS (2011)

Add to Collection

Article Medicine, Research & Experimental

A simulation-based comparison of the traditional method, Rolling-6 design and a frequentist version of the continual reassessment method with special attention to trial duration in pediatric Phase I oncology trials

Arzu Onar-Thomas et al.

CONTEMPORARY CLINICAL TRIALS (2010)

Add to Collection

Article Oncology

Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER plus breast cancer

Chad J. Creighton et al.

BREAST CANCER RESEARCH (2010)

Add to Collection

Article Oncology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. A. Eisenhauer et al.

EUROPEAN JOURNAL OF CANCER (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.